Despite being a preventable disease, cervical cancer is still the second most common cancer in women worldwide. HIV infection is associated with a higher incidence, more rapid progression, and increased recurrence rates of human papillomavirus (HPV)-associated cervical intra-epithelial neoplasia and invasive cancer. The disease burden in developing countries is the result of inadequate national health care infrastructures that cannot establish or sustain comprehensive screening programmes, together with a high prevalence of HIV infection, particularly in southern Africa. In this article, clinically relevant issues for primary prevention of cervical lesions by a quadrivalent HPV vaccine and the 'screen-and-treat' protocol in settings of high HIV prevalence will be explored.
Menon, S. (2011). Cervical cancer prevention in settings of high HIV prevalence. Southern African Journal of HIV Medicine. AOSIS (pty) Ltd. https://doi.org/10.4102/sajhivmed.v12i2.192